{
  "id": 5647358,
  "title": "President Spetzler sells $14.8m in Caris Life Sciences stock",
  "url": "https://urgent.news/2026/09/04/president-spetzler-sells-14-8m-in-caris-life-sciences-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T21:31:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/president-spetzler-sells-148m-in-caris-life-sciences-stock-93CH-4890066"
  },
  "original_language": "en",
  "account": "Caris Life Sciences President David Baxley Spetzler disposed of a significant portion of the company's stock on September 3 and 4, 2026. He sold $14,834,106 worth of common shares, while simultaneously purchasing $3,050,000 worth of shares through option exercises on the same days. The insider transactions occurred as Caris Life Sciences' stock price hovered around $25.07, giving the company a market capitalization of $7.16 billion. The stock was deemed overvalued by InvestingPro, although it had generated strong returns with a 26% gain over the past six months. Mr. Spetzler exercised options to acquire 1,000,000 shares at $2.44 per share on September 3, and subsequently sold 393,100 shares at prices ranging from $24.32 to $25.31. On September 4, he exercised options for an additional 250,000 shares at $2.44 per share and sold 119,212 shares at a weighted average price of $24.76. These sales were executed to cover the exercise price of the vested stock options and tax withholding obligations. The insider retained all remaining shares acquired through exercise. As a result, Mr. Spetzler now owns 1,182,871 shares of Caris Life Sciences common stock. Caris Life Sciences reported robust financial results for Q2 2026, exceeding revenue expectations and raising its full-year guidance. The company's molecular profiling services contributed to a 45% revenue growth from the previous year.",
  "summary": null,
  "key_points": [
    "President David Baxley Spetzler sold $14.8m in Caris Life Sciences stock on September 3-4, 2026",
    "Spetzler exercised options to acquire 1.3m shares and sold 512.3k shares on same days",
    "Caris Life Sciences reported Q2 2026 revenue growth of 45% and raised full-year guidance"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}